Semaglutide: UK regulator approves drug for prevention of cardiovascular events

BMJ. 2024 Jul 25:386:q1660. doi: 10.1136/bmj.q1660.
No abstract available

Publication types

  • News

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Cardiovascular Diseases* / prevention & control
  • Drug Approval*
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • United Kingdom

Substances

  • Glucagon-Like Peptides
  • semaglutide
  • Anti-Obesity Agents